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Background: Chronic renal failure (CRF) is associated with increased cardiovascular mortality, and medial vascular smooth
muscle cell (VSMC) hypertrophy, proliferation, and calcification play a pivotal role in uremic vasculopathy. Glucose
transporter-1 (GLUT1) facilitates the transport of glucose into VSMCs, and GLUT1 overexpression associated with high
glucose influx leads to a stimulation of VSMC proliferation. However, the role of GLUT1 in uremic vasculopathy remains
unclear. This study aimed to identify changes in the expression ofGLUT1 inVSMCs in the setting of experimental uremia and
investigate whether Akt/tuberous sclerosis complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal
S6 protein kinase (S6K) signaling, which plays a crucial role in VSMCproliferation and glucose metabolism, is involved in the
regulation of GLUT1 expression.
Methods: In vivo experimental CRFwas induced inWistar rats by 5/6nephrectomy, and theGLUT1 expression in aortic tissue
was determined by the reverse transcriptase-polymerase chain reaction, immunoblotting, and immunohistochemical staining.
Indoxyl sulfate (IS) is a uremic retention solute proven with pro-proliferative effect on rat VSMCs, and we further studied the
expression ofGLUT1 in rat A7r5 rat embryonic aortic cells stimulated by IS in the presence or absence of phloretin, aGLUT1
inhibitor, to explore the pathogenic role of GLUT1 in uremic vasculopathy. The contribution of Akt/TSC2/mTOR/S6K
signaling in modifying the GLUT1 expression was also assessed.
Results: Eight weeks after 5/6 nephrectomy, aortic tissue obtained from CRF rats exhibited increased wall thickness and
VSMC hypertrophy, hyperplasia, and degeneration. Compared with the sham-operated control group, the messenger
(m)RNA and protein abundance of GLUT1 were both markedly increased in CRF rats. In vitro, IS induced a significant
increase in expression of GLUT1 protein as well as pro-proliferative cyclin D1 and p21 mRNA and a modest increase in
expression of antiapoptotic p53 mRNA in A7r5 cells, whereas inhibition of GLUT1 mediated glucose influx reduced the
pro-proliferative and antiapoptotic effects of IS. In addition to increased GLUT1 expression, IS significantly suppressed Akt
and TSC2 phosphorylation after 6-hour and 12-hour treatment, but increased S6K phosphorylation after 3-hour treatment.
Inactivation of mTOR downstream signaling by rapamycin treatment inhibited S6K phosphorylation and abolished the
stimulatory effect of IS on GLUT1 expression.
Conclusions: In vivo and in vitro experimental CRF displayed prominent GLUT1 upregulation in VSMCs. The uremic toxin
IS stimulated proliferation of VSMCs possibly through induction of GLUT1 expression. The Akt/TSC/mTOR/S6K
signaling pathway may be one of the mechanisms underlying the upregulation of GLUT1 expression in uremic VSMCs.
(J Vasc Surg 2013;57:475-85.)
Clinical Relevance: This study revealed that experimental uremia is characterized by significant media hyperplasia and
hypertrophy in addition to prominent glucose transporter-1 (GLUT1) upregulation in aortic tissue. The expression of
GLUT1 in vascular smooth muscle cells can be stimulated by indoxyl sulfate through the Akt/tuberous sclerosis complex
subunit 2/mammalian target of rapamycin/ribosomal S6 protein kinase signaling pathway, a pivotal mechanism involved in
the regulation of cell growth, proliferation, and survival. In addition to emphasizing the important role of GLUT1 in uremic
vasculopathy, our study raised the possibility ofGLUT1 as a therapeutic target, and further studies arewarranted to dissect the
detailed molecular mechanisms of GLUT1 underlying vasculopathy in chronic kidney disease.
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February 2013476 Lin et alIt has been well established that cardiovascular compli-
cations are the leading cause of morbidity and mortality in
patients with chronic kidney disease (CKD) on dialysis.1 A
number of epidemiologic investigations reported that the
cardiovascular mortality rate in dialysis patients was 10-fold
to 30-fold higher than that in the general population after
stratification for age, sex, race, and the presence of diabe-
tes.1 Even early-stage of CKD has been confirmed to be a
powerful risk factor contributing to cardiovascular events.
CKD is associated with several cardiovascular diseases
(CVDs), including coronary artery disease, acute myocar-
dial infarction, peripheral vascular disease, left ventricular
hypertrophy, heart failure, pericarditis, valvular disease, ar-
rhythmia, and sudden death.2
Vascular calcification is a common histopathogenic fea-
ture in uremic vasculopathy and its extent and distribution
are good predictors of subsequent vascular mortality.3
There are two major types of vascular calcification. One is
atherosclerotic type, which occurs in the intima and con-
tributes to plaque formation and rupture. The other type is
Monckeberg sclerosis, also known as medial artery calcifi-
cation (MAC), which occurs in the media and leads to
vascular stiffening.4 MAC is commonly encountered in
patients with diabetes and CKD, suggesting they share a
similar pathogenic mechanism.5
Diabetes and insulin resistance are well-known risk
factors for the increased burden of CVD in patients with
CKD. Accumulating evidence has demonstrated a close
link between hyperglycemia and abnormal growth, migra-
tion, proliferation, and hypertrophy of vascular smooth
muscle cells (VSMCs).6,7 Recent studies have revealed that
the exposure of VSMCs to high glucose increases protein
kinase C activity, nuclear factor -B production, and oxi-
dative stress generation.8,9 In VSMCs, hyperglycemia acti-
vates mitogen-activated protein kinases (MAPKs),10 Janus-
family of activated kinases, and signal transducers and
activators of transcription,11 which are essential signaling
components involved in cell growth and proliferation.
Moreover, hyperglycemia stimulates VSMC migration
from the media into intimal atherosclerotic plaque and
induces matrix metalloproteinase production, resulting in a
tendency for plaque destabilization.12 Similar findings were
noted after exposure of VSMCs to high insulin concentra-
tions, which exerts atherogenic action through MAPK-
mediated enhancement of cell proliferation.13 In addition,
Avena et al14 demonstrated a synergic effect of glucose and
insulin on the proliferation of VSMCs that possibly contrib-
utes to the development of atherosclerosis. Thus, glucose
metabolism-related signaling pathways in VSMCs play a
pivotal role in the molecular mechanisms of vasculopathy in
CKD.
The protein family of facilitative glucose transporters
(GLUTs) comprises 14 isoforms that facilitate transport of
glucose down its concentration gradient and exhibit differ-
ent kinetic properties and tissue expression profiles. These
glucose transporters have been shown to play important
roles in the control of glucose utilization, glucose sensing,
and glucose sensing. GLUT1, the first member of the uacilitative GLUT family, is constitutively expressed on the
lasma membrane of most mammalian cells and is most
bundant in fibroblasts, erythrocytes, and vascular endo-
helium.15 In VSMCs, GLUT1 is the main isoform of
LUTs, which facilitates transport of glucose into cells and
re responsible for basal glucose uptake.15,16 The expres-
ion level of GLUT1 usually correlates with the rate of
ellular glucose metabolism,17-19 and upregulation of
LUT1 leads to an increase in intracellular glucose con-
entrations, resembling the diabetic milieu.20 In the ab-
ence of high extracellular glucose concentrations, GLUT1
verexpression promotes proliferation and prevents ap-
ptosis of VSMCs in vitro.21 Moreover, high glucose in-
uces VSMC calcification through the upregulation of
ore-binding factor subunit -1 and bone morphogenetic
rotein 2 expression,22 and a recent human study reported
hat the GLUT1 Xbal polymorphism is associated with
ascular calcification in nondiabetic uremic patients.23
These studies suggest that GLUT1-mediated high glu-
ose influx may participate in the pathogenesis of uremic
asculopathy. However, the effect of GLUT1 on vascular
isorders in CKD and the underlying molecular mecha-
isms are not established to date. However, mammalian
arget of rapamycin (mTOR) signaling pathway is a well-
nown regulator of cell proliferation and growth and has
een shown to participate in the regulation of VSMC
roliferation and glucose metabolism.24 We therefore hy-
othesized that dysregulation of GLUT1 may play a role in
he development of vasculopathy in CKD and the expres-
ion of GLUT1 is modulated by mTOR signaling.
To test this hypothesis, the expression of GLUT1 in the
orta was determined by semiquantitative reverse transcriptase-
olymerase chain reaction (RT-PCR),Western blotting, and
mmunohistochemical staining in a murine 5/6 nephrec-
omy chronic renal failure (CRF) model. Indoxyl sulfate
IS) is a uremic retention toxin proven with a stimulatory
ffect on rat VSMC proliferation, and the pathogenic role
f GLUT1 in uremic vasculopathy was investigated by
reating A7r5 rat embryonic aortic cells with IS in the
resence or absence of the GLUT1 inhibitor phloretin. To
urther dissect the underlying molecular mechanisms, the
ffects of the Akt/tuberous sclerosis complex subunit 2
TSC2)/mTOR/ribosomal S6 protein kinase (S6K) sig-
aling pathway on GLUT1 expression were assessed in
S-stimulated A7r5 cells.
ETHODS
The Animal Ethics Boards of the National Defense
edical Center (Taipei, Taiwan) approved all animal ex-
erimental protocols and procedures.
Animal experiments. Young adult male Wistar rats
initial weight, 220-250 g) were housed in a light- and
emperature-controlled room with ad libitum access to
eionized drinking water and standard chow (0.28% (wt/
t) NaCl, 1.0% (wt/wt) Ca, 0.22% (wt/wt)Mg; (LabDiet;
MI International, St. Louis, Mo). After a 1-week acclima-
ization period, the animals were randomly allocated to
ndergo a sham operation or 5/6 nephrectomy to induce
R
i
t
g
R
m
T
m
R
g
w
R
p
fi
(

(
(
w
(
the m
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Lin et al 477CRF. All operations were performed under anesthesia by
intraperitoneal injection of sodium pentobarbital (100
mg/kg, Sigma, St. Louis, Mo).
In the CRF group, eight rats underwent a two-stage
5/6 nephrectomy to induce CRF with renal function
equivalent to stages 3 to 4 CKD, as previously de-
scribed.25,26 During the first stage of nephrectomy, ap-
proximately two-thirds of the left kidney was removed after
ligating both the upper and lower poles through a lower
midline abdominal incision. One week later, the entire
right kidney was removed after ligating the vascular pedicle
through a dorsal lumbar flank approach. Eight rats under-
went sham operations, which involved a flank incision with
gentle manipulation of the kidney on the same day as the
CRF group underwent nephrectomy. Eight weeks later
after the second stage nephrectomy, the animals were eu-
thanized and blood and ascending aortic samples were
taken.
Serum biochemistry and blood pressure measu-
rement. Serum urea, creatinine, and glucose concentra-
tions were determined using an automated analyzer (AU
5000 Chemistry Analyzer; Olympus, Tokyo, Japan). The
systolic blood pressure of restrained conscious rats at
steady state was measured with a programmable tail-cuff
sphygmomanometer (MK-2000A; Muromachi, Tokyo,
Fig 1. Blood biochemistry values for sham-operated (n
(A) serum blood urea nitrogen (BUN), (B) creatinine, a
(SBP). Data are presented as means  standard error ofJapan). aRNA isolation and semi-quantitative RT-PCR.
NA was extracted from the rat aorta by homogenization
n Trizol (Invitrogen, Carlsbad, Calif), and the obtained
otal RNA was subjected to DNase treatment to prevent
enomic DNA contamination. Thereafter, 1.5 g of total
NA was reverse-transcribed usingMoloney murine leuke-
ia virus reverse transcriptase (Promega, Madison, Wisc).
he obtained complimentary (c)DNA was used to deter-
ine GLUT1, cyclin D1, p21, and p53 mRNA levels by
T-PCR. The expression level of the housekeeping gene
lyceraldehyde 3-phosphate dehydrogenase (GAPDH)
as used as an internal control to normalize differences in
NA extraction and reverse transcription efficiencies. The
rimer sequences (MdBio, Taipei, Taiwan) used for ampli-
cations were as follows:
GLUT1: 5=-CAT GTA TGT GGG GGA GGT GT-3=
forward) and 5=-GAC GAA CAG CGA CAC CAC AG
3= (reverse);
cyclin D1: 5=-ATG GAA CAC CAG CTC CTG TG-3=
forward) and 5=-CTT AGA GGC CAC GAA CAT GC-3=
reverse);
p21: 5=-GCT GTC TCC AGG AGG CCC G-3= (for-
ard) and 5=-GCT GGT CTG CCT CCG TTT TCG-3=
reverse);
p53: 5=-GCAACTATGGCTTCCACCTG-3= (forward)
nd chronic renal failure (CRF; n 8) rats are shown for
) glucose levels, along with (D) systolic blood pressure
ean. *P  .05 vs sham-operated rats. 8) a
nd (Cnd 5=-CACGAACCTCAAAGCTGTCC-3= (reverse);
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February 2013478 Lin et alGAPDH: 5=-ATG GGA AGC TGG TCA TCA AC-3=
(forward) and 5=-CCA CAG TCT TCT GAG TGG CA-3=
(reverse).
The expected amplification fragment lengths of GLUT1,
cyclin D1, p21, p53, and GAPDH were 458, 336, 308,
507, and 374 bp, respectively. The reaction parameters of
PCR were as follows: 94°C for 3 minutes, followed by 35
amplification cycles for GLUT1, 26 amplification cycles for
cyclin D1, p21, and p53, and 30 amplification cycles forrAPDH consisting of 94°C for 40 seconds, 59°C for 40
econds, and 72°C for 40 seconds, and a final extension at
2°C for 10 minutes. Amplification was performed in a
eneAmp PCR system 9700 thermocycler (Applied Bio-
ystems, Foster City, Calif). The PCR products were ana-
yzed by electrophoresis using 1% agarose gel and visualized
fter ethidium bromide staining and ultraviolet irradiation.
he densitometric analysis of band intensity was performed
sing ImageJ software (National Institutes of Health,
ethesda, Md), and the relative level of GLUT1 mRNA
xpression was determined by normalizing the band inten-
ity of GLUT1 to that of GAPDH.
Immunohistochemistry. The excised aortas were im-
ersion-fixed in 10% buffered formalin, embedded in par-
ffin, and cut at a thickness of 5 m on a microtome. The
araffin sections were deparaffinized and stained with he-
atoxylin and eosin to reveal general tissue morphology in
standard manner. Immunohistochemical staining was
erformed using an avidin-biotin-peroxidase complex de-
ection kit (Vectastain ABC Elite kit; Vector Laboratories,
urlingame, Calif). Endogenous peroxidase activity was
locked by immersing the sections in 3% hydrogen perox-
de for 5 minutes. After washing with phosphate-buffered
aline, the sections were incubated with 2% bovine serum
lbumin for 30 minutes at room temperature to block
onspecific binding. The sections were then drained well
nd incubated sequentially with primary antibody rabbit
nti-rat GLUT1 for 1 hours, biotinylated goat antirabbit
econdary antibody (1:60) for 45 minutes, and horseradish
eroxidase-conjugated streptavidin for 20 minutes at room
emperature. After each incubation, sections were washed
ith Tris-buffered saline/Tween (12.5 mMTris/HCl [pH
.6], 137 mM NaCl, 0.1% Tween 20) three times and
,3’-diaminobenzidine (Sigma) was added for 5 minutes,
fter which sections were finally counterstained with
ayer’s hematoxylin.
Pictures were taken with anOlympus BX51microscope
YuanLi Instrument Co Ltd, Taipei, Taiwan). Semiquanti-
ative analysis of tissue immunoreactivity for GLUT1 in rat
orta was done by two pathologists blinded both to the
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ig 2. Glucose transporter-1 (GLUT1) expression in aortic tissue
f chronic renal failure (CRF) rats. A, Representative semiquanti-
ative reverse transcriptase-polymerase chain reaction analysis of
LUT1 messenger RNA in aortic tissue from sham-operated and
RF rats. B, The amount of GLUT1 messenger RNA is expressed
s the ratio to glyceraldehyde-3-phosphate dehydrogenase
GAPDH) abundance and depicted as percentages of that in
ham-operated rats. C, Representative immunoblots of protein
amples from homogenates of aortic tissue of sham-operated and
RF rats were labeled with antibodies against GLUT1 or
APDH. D, GLUT1 protein expression was quantified by com-
uter-assisted densitometry analysis and presented as the ratio to
APDH expression levels, in relative percentages compared with
hose in sham-operated rats. Data are presented as means 
tandard error of the mean (n  8). *P  .05 vs sham-operated
ats.
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Volume 57, Number 2 Lin et al 479sample identification and experimental protocol using an
immunohistochemical rating score (IRS).27 In brief, the
intensity was rated as 0, no staining; 1, weak staining; 2,
moderate staining; and 3, strong staining. The amount of
positive stained cells was rated as 0, no cells; 1, 10%; 2,
10% to 50%; 3, 51% to 80%; and 4, 80%. For the calcula-
tion of IRS, the scores of intensity and amount of positive
cells were multiplied.
VSMC culture. The rat embryonic aortic smooth
muscle cell line, A7r5 (BCRC60082), was purchased from
the Bioresource Collection and Research Center in Taiwan.
Cells were grown in Dulbecco’s Modified Eagle’s Medium
Fig 3. Histology and immunohistochemistry of uremi
staining (original magnification 	400) of paraffin-embe
failure (CRF) rats. Representative images of immunohist
transporter-1 (GLUT1) protein in the aortae of (C) sham
GLUT1 protein was assessed by immunohistochemical
control. Data are presented as means  standard error o(DMEM) supplemented with 10% fetal bovine serum dFBS), 150 units/mL penicillin, and 150 mg/mL strepto-
ycin. Cells were incubated at 37°C in 5% CO2 and 95%
ir. Confluent cells were detached using a 0.05% trypsin/
.02% ethylenediaminetetraacetic acid solution and subcul-
ured to the second passage in 6-well cultures plates. The
ells were seeded at a density of 2 	 105 cells/well on
-well culture plates in DMEMwith 10% FBS for 72 hours.
fter serum starvation overnight in DMEMwith 0.5% FBS,
he cells were stimulated by the uremic compound IS with
LUT1 inhibitor phloretin or mTOR inhibitor rapamycin
Rapa) for 24 hours. In time-course experiments, the cells
ere treated with IS alone or together with Rapa for a serial
aorta. Representative images of hematoxylin and eosin
aortas from (A) sham-operated and (B) chronic renal
mical staining (original magnification 	400) of glucose
rated and (D) CRF rats. E, Semiquantification of aortic
score and is depicted as percentage of sham-operated
mean (n  8). *P  .05 vs sham-operated rats.c rat
dded
oche
-ope
ratingoubling incubation period (0, 3, 6, and 12 hours). IS was
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February 2013480 Lin et aldiluted from a 500 mg/mL stock solution prepared in
distilled water, which was used as the vehicle control.
Concentrations of IS, phloretin, and Rapa used in this
experiment were 250 M, 0.1 mM, and 25 nM, respec-
tively. All chemical compounds were purchased from
Sigma, and cell culture reagents were obtained from
GIBCO/BRL (Grand Island, NY).
Immunoblotting. The aortic tissue obtained from
CRF rats and cultured A7r5 cells were incubated with lysis
buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesul-
fonic acid [HEPES; pH 7.6], 150 mM sodium chloride,
0.5% Triton X-100, 10% glycerol, 0.1% sodium dodecyl
sulfate) containing protease inhibitor cocktails (Sigma) and
a phosphatase inhibitor mixture (PhosSTOP; Roche Ap-
plied Science, Indianapolis, Ind) at 4°C for 30 minutes.
The protein extracts were separated using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and subsequently
electrotransferred to polyvinylidene fluoride membranes
(Immobilon-P; Millipore, Bedford, Mass).
Blots were incubated with rabbit antirat GLUT1 poly-
clonal (1:500; Spring Bioscience, Pleasanton, Calif),
Fig 4. Glucose transporter-1 (GLUT1) protein abundance in vas-
cular smooth muscle cells treated with indoxyl sulfate (IS). A,
Representative immunoblots of total protein lysates isolated from
A7r5 cells exposed to IS (250 M) with and without rapamycin
(Rapa; 25 nM) for 24 hours were labeled with antibodies against
GLUT1 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
B,ExpressionofGLUT1proteinwas quantifiedby computer-assisted
densitometry analysis and presented as the ratio to GAPDH expres-
sion levels, in relative percentages compared with untreated control.
Data are presented as means  standard error of the mean (n  4).
*P .05 vs untreated control.Akt polyclonal (1:1000; Cell Signaling, Danvers, Mass), hhospho-Akt (p-Akt, phosphorylation at Ser 473) poly-
lonal (1:1000; Cell Signaling), TSC2 monoclonal
1:1000; Cell Signaling), phospho-TSC2 (p-TSC2, phos-
horylation at Thr 1462) monoclonal (1:500; Cell Signal-
ng), S6K monoclonal (1:1000; Cell Signaling), phospho-
6K (p-S6K, phosphorylation at Thr 389) polyclonal
1:1000; Cell Signaling), and GAPDH polyclonal
1:5000; Millipore) antibodies. Subsequently, the blots
ere incubated with a goat antirabbit horseradish
eroxidase-labeled secondary antibody (Sigma). Immuno-
eactive protein was detected by the enhanced chemilumi-
escence method (Pierce, Rockford, Ill).
Protein expression of the immunopositive bands was
uantified through pixel density scanning and computed
alculation using the Molecular Analyst software of Bio-
ad Laboratories (Hercules, Calif). The average pixel den-
ity of an area devoid of bands was subtracted from the
alues obtained for bands of interest in order to normalize
verage pixel density against background. Relative expres-
ion was determined by dividing the normalized average
ixel density of bands of interest by the average pixel
ensity of GAPDH.
Statistical analyses. Values are expressed as means 
tandard error of themean. Statistical significance (P .05)
etween groups was determined by an unpaired Student
-test. All analyses were performed using the Power PC
.51 software (StatView, Berkeley, Calif).
ESULTS
Serum biochemistry. The serum biochemical data
btained 8 weeks after nephrectomy are shown in Fig 1.
uccessful induction of CRF was confirmed by significantly
levated serum urea (45 10 vs 20 0.5mg/dL; P .04)
nd creatinine (1.2  0.3 vs 0.4  0.01 mg/dL; P  .04)
evels in CRF rats that underwent 5/6 nephrectomy com-
ared with levels in sham-operated rats. Serum glucose
evels were slightly lower in the CRF group (n 8) than in
he sham-operation group (n  8), but the difference did
ot reach statistical significance (204  11 vs 177  11
g/dL). Compared with sham-operated controls, CRF
ats exhibited a significant increase in systolic blood pres-
ure (120 3 vs 142 4mmHg; P .0007) measured by
he tail-cuff method.
GLUT1 mRNA and protein expression in uremic
orta. To investigate the role of GLUT1 in uremic vascu-
opathy, GLUT1 abundance in the aortas of CRF rats was
etermined by semiquantitative RT-PCR. The mRNA ex-
ression of GLUT1 was 1.9-fold higher in CRF rats than in
ham-operated rats (192%  16% vs 100%  9%; P  .04;
ig 2, A and B). Consistent with mRNA expression levels,
RF rats exhibited a 2.4-fold increase in GLUT1 abun-
ance compared with that in the sham-operation group
236%  14% vs 100%  29%; P  .03; Fig 2, C and D).
Immunohistochemical staining of GLUT1 in ure-
ic aortas. In CRF rats, the aortic tissue sections stained
ith hematoxylin and eosin exhibited increasedwall thickness,
ntimal edema, and vascular smooth muscle hypertrophy,
yperplasia, and degeneration by subjective observations (Fig
JOURNAL OF VASCULAR SURGERY
Volume 57, Number 2 Lin et al 481Fig 5. Effect of indoxyl sulfate (IS) on glucose transporter-1 (GLUT1) expression and the Akt/tuberous sclerosis
complex subunit 2 (TSC2)/mammalian target of rapamycin (mTOR)/ribosomal S6 protein kinase (S6K) signaling
pathway in vascular smooth muscle cells (VSMCs). A, Representative immunoblots of GLUT1 expression and the
Akt/TSC2/mTOR/S6K signaling pathway in VSMCs incubated with IS (250M)with or without rapamycin (Rapa)
for 3, 6, or 12 hours. GLUT1 protein expression and Akt, TSC2, and S6K phosphorylation were quantified by
computer-assisted densitometry analysis and presented as the ratio to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH). B, Levels of phospho-protein immunoreactivity were normalized to their respective total protein immu-
noreactivity and are expressed as the percent of control. Data are presented as means  standard error of the mean
(n  4). *P  .05 vs untreated control (0 hours); #P  .05 vs without treatment with Rapa for the same period.
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February 2013482 Lin et al3,A andB).We further evaluated the distribution and expres-
sion of GLUT1 in aortas by immunohistochemical staining
and found that GLUT1 was mainly detected in both the
endothelium and VSMCs (Fig 3, C and D). As assessed by
semiquantitative scoring, the staining intensity for GLUT1
protein staining was more prominent in CRF rats than in
sham-operated rats (9.3  1.2 vs 2.7  0.2; P  .003; Fig
3, E).
Effects of IS on the expression of GLUT1 and
associated signaling pathways in VSMCs. To confirm
previous in vivo findings, A7r5 cells were incubated with IS,
a uremic compound, to mimic the in vivo conditions of
uremia. In line with these findings, IS at a concentration of
250 M, which is comparable with its mean serum level in
patients on hemodialysis,28 induced a 1.4-fold increase in
GLUT1 protein expression in A7r5 cells compared with its
expression in the vehicle controls (141%  9% vs 100% 
7%; P  .01; Fig 4, A and B).
We further investigated the role of Rapa, an mTOR
inhibitor, in the regulation of GLUT1 in vitro. Rapa alone
did not exert a significant effect on GLUT1 expression in
A7r5 cells. However, the stimulatory effect of IS on the
abundance of GLUT1 was abolished in the presence of
Rapa (Fig 4, A and B).
To further elucidate the signaling pathway involved in
the upregulation of GLUT1, we investigated the time-
course effects of IS onmTOR-related signaling in vitro (Fig
5). Compared with untreated control (0 hours), the pro-
tein expression of GLUT1 was induced by incubating A7r5
cells with IS for 3, 6, and 12 hours (control: 100%  16%,
3 hours: 216%  19%, 6 hours: 181%  20%, 12 hours:
168%  10%; 3 hours vs control, P  .009; 6 hours vs
control, P  .036; 12 hours vs control, P  .028) and
suppressed by the coincubation of IS with Rapa for 3 hours
(216%  19% IS vs 111%  3% IS 
 Rapa; P  .029). In
addition to increased GLUT1 expression, IS significantly
suppressed Akt phosphorylation at Ser 473 after 6-hour
(P  .05) and 12-hour (P  .01) treatments (control:
100%  10%, 6 hours: 58%  10%, 12 hours: 30%  11%;
6 hours vs control, P .04; 12 hours vs control, P .009),
whereas Rapa reversed the effect of IS on Akt phosphory-
lation after stimulation for 12 hours (30%  11% IS vs
91% 10% IS
Rapa; P .017). Similarly, IS significantly
decreased TSC2 phosphorylation at Thr 1462 after 12-
hour treatment (control: 100%  1% vs 12 hours: 34% 
13%; P  .034), which was abolished by the addition of
Rapa. S6K phosphorylation was slightly increased by IS
incubation for 3 hours (control: 100%  17% vs 3 hours:
131%  7%), whereas Rapa significantly suppressed S6K
phosphorylation after 3-hour (131%  7% IS vs 0% IS 

Rapa; P  .003), 6-hour (100%  4% IS vs 0% IS 
 Rapa;
P  .002), and 12-hour (85%  11% IS vs 0% IS 
 Rapa;
P  .015) treatments.
The role of GLUT1 in uremic VSMCs. To investi-
gate the role of GLUT1 in uremic vasculopathy, the expres-
sions of pro-proliferative cyclin D1 and p21 genes29 and
antiapoptotic p53 gene30 were determined in A7r5 cells
treated with IS (250 M) alone or together with GLUT1 fnhibitor phloretin (0.1 mM). Compared with untreated
ontrol, IS induced a significant increase in mRNA expres-
ion of cyclin D1 (147%  5% vs 100%  0.2%; P  .025)
nd p21 (273%  24% vs 100%  11%; P  .021) and a
odest increase in p53 (110%  12% vs 100%  5%; P 
06) mRNA expression. Treatment with phloretin and IS vs
S treatment alone markedly attenuated the pro-proliferative
yclin D1 (147%  5% vs 39%  2%; P  .0003) and p21
273%  24% vs 66%  10%; P  .003) mRNA expression
nd antiapoptotic p53 (110% 12% vs 29% 9%; P .011)
RNA expression in A7r5 cells (Fig 6).
ISCUSSION
Cardiovascular mortality is the primary cause of death
n uremic patients, and medial calcification rather than
therosclerosis is the main pathologic characteristic of vas-
ulopathy.1,4 In line with previous findings,31 experimental
remia induced by 8-week 5/6 nephrectomy induced vas-
ular smooth muscle hyperplasia and hypertrophy, accom-
anied by elevated serum urea and creatinine levels and
levated blood pressure, consistent with the clinical and
istologic manifestations of human CKD. In the present
tudy, we observed that the marked morphologic changes
f uremic aortas were associated with increased mRNA and
rotein expression of GLUT1 as well as increased immu-
ohistochemical staining of GLUT1. In vitro, we further
emonstrated that IS, a representative uremic toxin, stim-
lated the expression of GLUT1 in the rat SMC line A7r5.
aken together, these data suggested that GLUT1 overex-
ressionmight play some role in the pathogenesis of uremic
asculopathy.
Diabetes is associated with an increased risk of car-
iovascular disorders, and hyperglycemia activates a
roatherogenic phenotype in all cell types in the vessel
all.6 High glucose promotes monocyte adhesion to the
ndothelial cells by activation of nuclear factor -B and
educes nitric oxide production, leading to substantial im-
airment of endothelium-dependent relaxation.7 Similarly,
yperglycemia results in the production of reactive oxygen
nd nitrogen species, which leads to oxidative myocardial
njury.32 In VSMCs, high glucose concentration can stim-
late their proliferation and migration and enhance the
eneration of chondroitin and dermatan sulfate proteogly-
ans, which might contribute to atherogenesis.6,7,9
LUT1 facilitates the transport of glucose across the
lasma membranes of mammalian cells, and its expression
evels have been shown to correlate well with intracellular
lucose concentration.17-19 GLUT1 has been detected in
ndothelial cells,33 VSMCs,17-19 as well as cardiomy-
oytes,34,35 and emerging evidence supports an important
ole of GLUT1 in the maintenance of normal cardiovascu-
ar function.
Recently, a murine genetic model (sm22-GLUT1
ice) established to investigate the role of GLUT1 in
SMCs by overexpressing of GLUT1 using the smooth
uscle protein 22- (sm22) promoter demonstrated that
ncreased GLUT1 expression in VSMCs enhanced trans-
orming growth factor (TGF)- activity and resulted in
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mice displayed impaired vascular contractility due to de-
creased fibronectin expression and a significant increase of
monocyte chemoattractant protein-1 (MCP-1) levels in
response to vascular injury, suggesting that GLUT1 is
essential for the maintenance of normal VSMC function.36
Furthermore, Hall et al21 demonstrated a significant in-
crease of GLUT1 protein abundance in neointimal tissuecfter balloon-induced injury in rabbits. These findings fur-
her support a pathogenic role of GLUT1 in vascular
isorders.
In VSMCs, we found that GLUT1 overexpression
ould be detrimental, possibly resulting in vasculopathy in
xperimental renal failure. However, a protective role of
LUT1 has been reported in endothelial cells33 and car-
iac myocytes.34,35 Nitric oxide-dependent endothelial re-
axation was significantly reduced in aortas obtained from
LUT1-deficient mice, suggesting that GLUT1 plays an
mportant role in regulating endothelial function.33 The
ardiac-specific GLUT1 overexpression may prevent the
evelopment of heart failure and left ventricular dilatation
fter chronic pressure overload in mice34 and could provide
rotection against ischemic reperfusion injury in aged
ice.35 These data suggested distinct roles of GLUT1 in
ifferent cardiac tissues and the discrepancy requires further
nvestigations.
IS, a metabolite of tryptophan, is a representative ure-
ic toxin, and serum IS levels are markedly increased in
remic patients compared with those in healthy individu-
ls.37 Previous studies have shown that IS stimulates rat
SMC proliferation associated with MAPK activation28
nd induces oxidative stress and the expression of osteo-
last-specific proteins in human VSMCs.37 In this study,
e demonstrated that IS stimulated the expression of
LUT1 accompanied by upregulation of pro-proliferative
yclin D1 and p21 genes and antiapoptotic p53 gene
xpression in rat VSMCs, which was suppressed by phlor-
tin, an inhibitor of GLUT1-mediated glucose transport,
uggesting a potential role of GLUT1 in the regulation of
remic toxin-induced VSMC proliferation.
In accordance with our findings, previous studies sug-
est an essential role of GLUT1 overexpression in VSMC
roliferation. The possible underlying mechanisms have
een indicated to involve the inhibition of apoptosis, which
s associated with inactivation of GSK-3 and c-Jun-NH2-
erminal kinase18,21,38 and increasing caspase-8 binding by
-Fas-associated death domain-like IL-1-converting en-
yme inhibitory protein.19 Collectively, GLUT1 upregula-
ion possibly contributes to VSMC proliferation via the
nhibition of apoptosis. Interestingly, the initiation of vas-
ular calcification could be retarded by inhibition of apo-
tosis through a caspase-dependent pathway.39 Thus,
™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™™
ig 6. Effects of glucose transporter-1 (GLUT1) inhibitor on the
xpression of pro-proliferative and antiapoptotic genes in indoxyl
ulfate (IS)-stimulated vascular smooth muscle cells. A, Represen-
ative semiquantitative reverse transcriptase-polymerase chain re-
ction analysis of cyclin D1, p21, and p53 messenger RNA expres-
ion in A7r5 cells treated with IS (250 M) with or without
LUT1 inhibitor phloretin (Phlo; 0.1 mM). B-D, The amount of
essenger RNA was expressed as the ratio to glyceraldehyde-3-
hosphate dehydrogenase (GAPDH) abundance and depicted as
ercentages of that in untreated control. Data are presented as
eans standard error of the mean (n 3). *P .05 vs untreated
ontrol; # P  .05 vs treatment with IS.
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lar calcification and further studies are warranted to dissect
the relationship betweenGLUT1 and vascular calcification.
The mTOR signaling pathway plays key roles in cellular
metabolism, hypertrophy, and hyperplasia. It acts as a cen-
tral regulator of protein synthesis and ribosome biogenesis
by sensing energy, nutrients, and stress. The signaling
network of mTOR includes upstream effectors Akt and
TSC2 and downstream effector S6K, which has been
shown to be involved in the onset and progression of
cancer, aging, and diabetes. Akt directly phosphorylates
TSC2, and these phosphorylation events release mTOR
from the inhibitory effects of TSC1-TSC2 complex. Acti-
vation of mTOR subsequently phosphorylates and activates
S6K, leading to an increase in ribosome biogenesis and an
initiation of protein synthesis.24
In the present study, we demonstrated that IS stimu-
lated the expression of GLUT1 in rat VSMCs, which was
suppressed by Rapa, an inhibitor of mTOR signaling, sug-
gesting that mTOR signaling plays a role in the regulation
of uremic toxin-induced GLUT1 expression in VSMCs.
We further dissected the underlying molecular mechanisms
by investigating the correlations between the phosphoryla-
tion profiles of Akt/TSC2/mTOR/S6K signaling pathway
and GLUT1 expression in IS-treated A7r5 cells. Our re-
sults showed that IS suppressed Akt and TSC2 phosphor-
ylation and induced the phosphorylation of the mTOR
downstreaming effector S6K associated with GLUT1 up-
regulation in VSMCs. In contrast, Rapa, an mTOR inhib-
itor almost completely suppressed the phosphorylation of
S6K and reduced the stimulatory effect of IS on GLUT1
expression. In line with our findings, silencing of the Akt
substrate TBC1D1 strongly increased GLUT1 expression
through mTOR/S6K pathway activation in 3T3-L1 adi-
pocyte.40 Moreover, GLUT1 expression can be modulated
by glycogen synthase kinase-3 via a TSC2/mTOR depen-
dent pathway in VSMCs.17,21 Taken together, IS induced
GLUT1 expression through the Akt/TSC2/mTOR/S6K
signaling pathway and possibly contributed to VSMC pro-
liferation in experimental renal failure. However, the peak
expression of GLUT1 expression did not correlate well
with the timing of maximal phosphorylation of Akt and
TSC2 in our study. This inconsistency may be due to the
negative feedback effect of S6K on Akt activation, post-
translation regulation of GLUT1 expression, or the pres-
ence of other mechanisms involved in the regulation of
GLUT1 expression.
CONCLUSIONS
CRF rats exhibited prominent medial hyperplasia and
hypertrophy in addition to GLUT1 upregulation in aortic
tissue. The uremic toxin IS stimulated proliferation of
VSMCs possibly through induction of GLUT1 expression.
The Akt/TSC/mTOR/S6K signaling pathwaymay be one
of the mechanisms underlying the upregulation of GLUT1
expression in uremic VSMCs, which is inhibited by Rapa.
Further studies are warranted to dissect the detailed molec-
ular mechanisms of GLUT1 underlying vasculopathy inKD and to investigate a possible therapeutic role of
LUT1.
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